Designed to dramatically improve survival and quality of life, the HeartMate II™ was developed with the goal of providing circulatory support for a broad range of advanced heart failure patients. Prehospitalresearch.euAre you a Critical Care Paramedic or a Paramedic who’s involved in the care or transport of patients on Ventricular Assist Devices (VADs)? The HeartMate II is placed below the diaphragm in the abdomen.
Incorporated in 1976, Thoratec is headquartered in Pleasanton, California.  HeartMate II was CE Mark authorized for bridge to transplantation and for destination therapy in Europe in November 2005. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. In 2015 the company was acquired by St. Jude Medical, a global medical-device company headquartered in Saint Paul, Minnesota. The HeartMate II™ is Abbott's first-line intermediate-to-chronic left ventricular assist device.  After reviving the company's profitability, Grossman left Thoratec in 2006 as the company was bringing the HeartMate II to market. , In December 1995 Thoratec received FDA approval to sell its Thoratec Ventricular Assist Device System, an external blood pump with cannulae connecting the pump to the patient's heart and vessels. - September 17, 2015, Missouri Court of Appeals Mean age was 14.5 years (range 5–18 years), mean weight was 57 kg (range 17–118 kg), and mean body surface area was 1.6 m2 (range 0.7–2.3 m2).  It received FDA approval for bridge-to-transplantation (BTT) use in April 2008, and for destination therapy (DT) for those too old or ill for a heart transplant in January 2010. Based on exhaustive research, it is a simpler, more efficient and engaging way for agents to positively interact with customers.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS", "Landmark Clinical Trial At 22 Medical Centers Finds Implanted Heart Pumps Lengthen And Improve Lives Of Terminally Ill Heart Failure Patients", "FDA approves use of improved HeartMate XVE for destination therapy", "Thoratec: FDA approval for TLC-II Portable Ventricular Assist Device", "VAD Therapies for Wide Range of Cardiac Conditions", "Giving a Heart a Hand: A New Mechanical Pump Offers Heart-Failure Patients an Alternative to a Transplant", HeartMate II Left Ventricular Assist System: Clinical Operation and Patient Management, HeartMate II Left Ventricular Assist Device (LVAD) Fact Sheet, "HeartMate II approved as destination therapy", "FDA Approves Left Ventricular Assist System for Severe Heart Failure Patients", "FDA approves Heartmate II for patients with severe heart failure", "Extended Mechanical Circulatory Support with a Continuous-Flow Rotary Left Ventricular Assist Device", A Clinical Trial to Evaluate the HeartWare Ventricular Assist System (ENDURANCE), "Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy", "Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology", "Deals Roundup: Thoratec Buys Catheter Pump Technology for $8.5M in Cash", "Thoratec acquires catheter-based heart pump technology from Getinge", "VAD Maker Thoratec Acquires Levitronix, Pediatric Device", "Thoratec Announces Acquisition of Medical Business of Levitronix", "Thoratec acquires DuraHeart II ventricular assist system", "Thoratec Acquires DuraHeart II Ventricular Assist System", "Deals Roundup: Thoratec Acquires DuraHeart II for Upfront Payment of $13M", "Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis", "4 Deaths Linked To Thoratec Heart System", "Thoratec issues warning about heart pump controller linked to four deaths", "Thoratec warns of heart pump's link to 4 patient deaths", "Thoratec Corp. Charlene Dewey, by and through Her Guardian ad Litem, Rodney Boyd, Appellant, vs. Barnes-Jewish Hospital, The Washington University Thoratec Corporation and Nancy Olson, Respondents.
 This enabled patients to return home with the system to await heart transplantation or for their native heart to recover.